Pharmacologic Approaches to Diabetes Management: Glucagon-Like Peptide-1 Based Therapies

Course overview

While glucose control is paramount for patients with diabetes, the American Diabetes Association (ADA) Standards of Care 2023 Diabetes guidelines also emphasize the importance of managing comorbidities that can complicate diabetes management. Subsequently, the guidelines highlight the benefits of glucagon-like peptide 1-based therapies. This course will review glucagon-like peptide-1-based therapies, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RAs. Dosing regimens, side effects, and monitoring parameters will be discussed. The role of GLP-1-based therapies within therapeutic regimens for patients with Type 2 diabetes will be discussed in the context of the updated Standards of Care in Diabetes 2023 guidelines.